English  |  正體中文  |  简体中文  |  Post-Print筆數 : 27 |  Items with full text/Total items : 92429/122733 (75%)
Visitors : 26428987      Online Users : 516
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://nccur.lib.nccu.edu.tw/handle/140.119/130953


    Title: 從開放式創新觀點探討知識網絡管理對創新績效之影響-以台灣生技製藥廠商為例
    Discuss the impact of knowledge network management on innovation performance from an open innovation perspective- cases study of Taiwan Biotech Pharmaceuticals companies
    Authors: 張筑莉
    Chang, Ju-Li
    Contributors: 吳豐祥
    Wu, Feng-Shang
    張筑莉
    Chang, Ju-Li
    Keywords: 開放式創新
    生技製藥業
    知識網路
    合作網路
    創新績效
    Date: 2013
    Issue Date: 2020-08-03 17:30:57 (UTC+8)
    Abstract: 近年來,生技及製藥產業近年競爭加劇且成長率趨緩。廠商面臨研發費用逐漸攀升,但最終通過FDA准許上市的數量下降等開發困境,因此,提升研發效率成為生技製藥廠商的重要挑戰。台灣生技製藥蓬勃發展,廠商陸續投入新藥開發。由於生物製藥是屬於高知識和技術密集的產業,它需要許多不同專業領域的結合,包括分子生物、藥理學、病理學、化學工程等,因此新藥開發需要跨領域之整合技術。有別於過去藥廠都較為仰賴垂直整合流程之內部開發,現在生技及製藥廠商則多轉為開放式之開發,向外尋找技術和資源,透過委外、授權、策略聯盟等方式的專業分工合作完成藥物開發。
    開放式創新之模式已逐漸廣為國外生技製藥廠商採用,而台灣生技製藥產業尚未成熟,新創的生技公司規模偏小,且許多研發能量落在研究與學術機構,因此,更需藉由開放式創新之研發模式進行新藥開發,以提升開發之創新成果。
    本研究的方法主要是採個案研究法,首先,先透過新藥開發流程與內外部情境、知識網絡型態、創新績效等相關的文獻分析,導出本研究之觀念性架構。接著延伸此架構進一步設計出個案訪談的問題,著重於探討台灣生技製藥廠商建構其知識網絡型態之因素,以及在不同開發階段,生技製藥廠商採取何種知識網絡之管理策略,以提升知識網絡之綜效與創新績效。
    本研究所得到的主要結論,包括:(1)台灣生技製藥廠商從事新藥或技術開發時,會傾向從臨床前研究或臨床試驗切入,且先以單一專案開始跨入新藥開發,並專注於特定的疾病領域。(2)台灣生技製藥廠商初期階段的技術來源主要以國家型實驗室、學術研究機構、技術授權廠商為主,在臨床試驗設計與推動借助關鍵意見領袖之醫師和專家的影響力,情感連結大於任務目的。(3)台灣生技製藥廠商在執行委外時,會仰賴有效的合約管理,並以任務關係導向為主。(4)台灣生技製藥廠商從事新藥或技術開發時,會透過技術授權、併購、共同研發等方式來取得外部技術和知識。此種作法對於開發的達成率、速度、能力的提升上都有很大的幫助。(5)台灣生技製藥廠商傾向於不設廠,而是透過外包CRO或CMO來快速獲得製程或研究的資源,並提升快速因應外界環境變化的能力。
    Reference: Baldwin, Carliss, & Von Hippel, Eric. (2010). Modeling a paradigm shift: From producer innovation to user and open collaborative innovation. Harvard Business School Finance Working Paper(10-038), 4764-4709.
    Chesbrough, Henry. (2004). Managing open innovation. Research Technology Management, 47(1), 23-26.
    Chesbrough, Henry. (2006). Open innovation: The new imperative for creating and profiting from technology. Harvard Business School Press Books, 1.
    Chesbrough, Henry. (2012). Open Innovation. Research Technology Management, 55(4), 20-27. doi: 10.5437/08956308X5504085
    Chesbrough, Henry, & Prencipe, Andrea. (2008). Networks of innovation and modularity: A dynamic perspective. International Journal of Technology Management, 42(4), 414-425. doi: 10.1504/IJTM.2008.019383
    Chesbrough, Henry W. (2003). The era of open innovation. MIT Sloan Management Review, 44(3), 35-41.
    Chesbrough, Henry W. (2006). Open business models: How to thrive in the new innovation landscape. Harvard Business School Press Books, 1.
    DiMasi, J. A. (2002). The value of improving the productivity of the drug development process: Faster times and better decisions. PharmacoEconomics, 20(15), 1-10.
    DiMasi, Joseph A. (2001). Winners and losers in new drug innovation. Medical Marketing & Media, 36(9), 98.
    Dimasi, Joseph A., & Grabowski, Henry G. (1995). R&D costs, innovative output and firm size in the pharmaceutical industry. International Journal of the Economics of Business, 2(2), 201.
    DiMasi, Joseph A., Hansen, Ronald W., & Grabowski, Henry G. (2003). The price of innovation: New estimates of drug development costs. Journal of Health Economics, 22(2), 151. doi: 10.1016/S0167-6296(02)00126-1
    Erickson, Bonnie H. (1985). Applied network analysis: A methodological introduction (Book Review). Social Forces (University of North Carolina Press), 63(3), 856-858.
    Granovetter, Mark S. (1973). The strength of weak ties. American journal of sociology, 1360-1380.
    Guler, Isin, & Nerkar, Atul. (2012). The impact of global and local cohesion on innovation in the pharmaceutical industry. Strategic Management Journal, 33(5), 535-549. doi: 10.1002/smj.957
    Hsu, Yeou-Geng, Shyu, Joseph Z, & Tzeng, Gwo-Hshing. (2005). Policy tools on the formation of new biotechnology firms in Taiwan. Technovation, 25(3), 281-292.
    Kirkman, Dorothy M. (2011). Knowledge management strategies in an open innovation environment. Allied Academies International Conference: Proceedings of the Academy of Strategic Management (ASM), 10(1), 53-59.
    Marsden, Peter V, & Campbell, Karen E. (1984). Measuring tie strength. Social forces, 63(2), 482-501.
    Mason, J., & Freemantle, N. (1998). The dilemma of new drugs: Are costs rising faster than effectiveness? PharmacoEconomics, 13(6), 653-657.
    Moody, James, & White, Douglas R. (2003). Structural cohesion and embeddedness: A hierarchical concept of social groups. American Sociological Review, 68(1), 103-127.
    Nonaka, Ikujiro. (2007). The knowledge-creating company. Harvard Business Review, 85(7/8), 162-171.
    Ozman, Muge. (2011). Modularity, industry life cycle and open innovation. Journal of Technology Management & Innovation, 6(1), 26-37.
    Powell, Walter W. (1990). Neither market nor hierarchy: Network forms of organization. Research in Organizational Behavior, 12, 295.
    Reagans, Ray, & McEvily, Bill. (2003). Network structure and knowledge transfer: The effects of cohesion and range. Administrative Science Quarterly, 48(2), 240-267.
    Research Challenges. (2008). Drug Discovery & Development, 12-14.
    Simard, Caroline, & West, Joel. (2006). Knowledge networks and the geographic locus of innovation. Open innovation: researching a new paradigm, 220-240.
    Thorelli, Hans B. (1986). Networks: between markets and hierarchies. Strategic Management Journal, 7(1), 37-51.
    Tortoriello, Marco, Reagans, Ray, & McEvily, Bill. (2012). Bridging the knowledge gap: The influence of strong ties, network cohesion, and network range on the transfer of knowledge between organizational units. Organization Science, 23(4), 1024-1039. doi: 10.1287/orsc.1110.0688
    Zack, Michael H. (1999). Developing a knowledge strategy. California Management Review, 41(3), 125-145.
    [An analysis of the strategic relationship among R&D portfolio risk levels, research resources input, and technology sources-The cases of Biotech & Pharmaceutical industry in Taiwan]. 管理學報, 21(6), 827-843.
    王佩瑩 (2006). 廠商技術來源對創新績效之研究~ 以全球前四大製藥公司為例. 成功大學高階管理碩士在職專班學位論文(2006 年), 1-60.
    王振寰, & 陳琮淵 (2009) 台灣的生技製藥產業: 發展, 創新與限制.
    胡哲生, 游志青, & 許逸平 (2004). 研發風險、研發資源投入與研發技術來源之策略關聯性研究-以臺灣生技製藥業為例.
    陳雅美 (2002a) 産業合作網絡形成原因的探討-以臺灣半導體産業爲例. 運籌研究集刊(1), 125-151.
    陳雅美 (2002b) 産業合作網絡形成原因的探討-以臺灣半導體産業爲例. [Industrial Cooperative Network-A Case Study on Taiwan Semi-conductor Industry]. 運籌研究集刊(1), 125-151.
    劉孝從 (2008) 台灣生技製藥業之新藥開發流程-開放式創新管理觀點. 政治大學. Available from Airiti AiritiLibrary database. (2008年)
    Description: 碩士
    國立政治大學
    科技管理研究所
    100359024
    Source URI: http://thesis.lib.nccu.edu.tw/record/#G0100359024
    Data Type: thesis
    DOI: 10.6814/NCCU202000712
    Appears in Collections:[科技管理研究所] 學位論文

    Files in This Item:

    There are no files associated with this item.



    All items in 政大典藏 are protected by copyright, with all rights reserved.


    社群 sharing

    著作權政策宣告
    1.本網站之數位內容為國立政治大學所收錄之機構典藏,無償提供學術研究與公眾教育等公益性使用,惟仍請適度,合理使用本網站之內容,以尊重著作權人之權益。商業上之利用,則請先取得著作權人之授權。
    2.本網站之製作,已盡力防止侵害著作權人之權益,如仍發現本網站之數位內容有侵害著作權人權益情事者,請權利人通知本網站維護人員(nccur@nccu.edu.tw),維護人員將立即採取移除該數位著作等補救措施。
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback